Ambit hit hard after quizartinib news

Ambit Biosciences (AMBI) comes off a halt and promptly drops 37%.

For more, see: ABMI will not seek accelerated approval for quizartinib based on Phase 2 data

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs